Article Details

JPMorgan Chase & Co. Reaffirms “Overweight” Rating for AstraZeneca (LON:AZN)

Retrieved on: 2019-09-03 05:11:15

Tags for this article:

Click the tags to see associated articles and topics

JPMorgan Chase & Co. Reaffirms “Overweight” Rating for AstraZeneca (LON:AZN). View article details on hiswai:

Excerpt

<div>AstraZeneca (LON:AZN)'s stock had its “overweight” rating reiterated by stock analysts at JPMorgan Chase & Co. in a research report issued on Friday ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up